8-K: Aptose Biosciences Acquired by Hanmi for C$2.41/Share

Aptose Biosciences will be acquired by Hanmi Pharmaceutical for C$2.41 per share in cash, representing a 28% premium, to advance the TUSCANY clinical study.

Summary

• Aptose Biosciences Inc. (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd., along with its subsidiary HS North America Ltd., have entered into a definitive arrangement agreement.
• Hanmi Purchaser will acquire all outstanding common shares of Aptose not currently owned or controlled by Hanmi Purchasers or their affiliates.
• Hanmi currently owns 19.93% of Aptose's outstanding Common Shares and has provided over US$30 million in debt facilities to support tuspetinib (TUS) development over the past 18 months.
• Minority shareholders will receive C$2.41 in cash per Common Share, representing a 28% premium over Aptose's 30-day Volume-Weighted Average Price (VWAP) of C$1.88 on the Toronto Stock Exchange (TSX).
• The transaction includes the surrender and cash exchange of Aptose options, restricted share units, and warrants (including Armistice Warrants valued using the Black Scholes model).
• The transaction is structured as a plan of arrangement under the Business Corporations Act (Alberta), following a continuance from the Canada Business Corporations Act.
• Post-completion, Aptose will no longer be subject to Canadian securities reporting requirements, and its shares will be delisted from all stock exchanges, including the TSX.
• The Special Committee, consisting of independent Board members, and the full Board of Directors unanimously recommended the arrangement, deeming it fair to minority shareholders and in Aptose's best interests.

Sentiment

Score: 8

Explanation: The acquisition provides a significant premium and immediate liquidity to shareholders, while ensuring the continued development of a promising drug candidate under the backing of a larger pharmaceutical company. This de-risks the asset for shareholders who receive cash, and provides a clear path forward for the drug.

Positives

• Minority shareholders receive a significant premium of 28% over the 30-day VWAP (C$2.41 vs. C$1.88), providing immediate cash value and liquidity.
• The transaction ensures the continued and uninterrupted development of tuspetinib (TUS) in the TUSCANY Phase 1/2 clinical study for acute myeloid leukemia (AML).
• TUS+VEN+AZA triplet therapy has shown promising response rates and safety, with 100% complete remission (CR/CRh) achieved in the 80mg and 120mg cohorts, including patients with difficult-to-treat mutations.
• Hanmi establishes its first direct entry and strategic foothold in North America, positioning for future partnerships and clinical expansion in the region.
• The Special Committee and Board unanimously approved the transaction, finding it fair from a financial point of view and in the best interests of Aptose.

Negatives

• Aptose will cease to be a publicly traded company, leading to its delisting from the TSX and other exchanges.
• Minority shareholders will no longer participate in potential future upside from tuspetinib's development beyond the C$2.41 per share.
• The company will no longer be subject to Canadian securities reporting requirements, reducing transparency for former public shareholders.
• An expense fee of C$300,000 is payable to Hanmi Purchaser if the Arrangement Agreement is terminated under certain circumstances.

Risks

• The transaction may not be completed on the contemplated terms, timing, or at all, due to a failure to obtain required regulatory, shareholder, and court approvals.
• Competing offers or acquisition proposals could emerge, potentially disrupting the current agreement.
• Failure to complete the transaction for any reason could negatively impact Aptose's share price or business operations.
• Hanmi Purchaser's failure to pay the cash consideration at completion of the Transaction.
• The business of Aptose may experience significant disruptions, including loss of employees, due to transaction-related uncertainty, industry conditions, or other factors.
• Risks related to employee retention during and after the acquisition process.
• The risk of regulatory changes that may materially impact the business or operations of Aptose.
• Risks related to the diversion of management's attention from Aptose's ongoing business operations while the Transaction is pending.

Future Outlook

Aptose Biosciences will become a privately held company under Hanmi Pharmaceutical, allowing for the uninterrupted and expanded development of tuspetinib (TUS) in the TUSCANY Phase 1/2 clinical study for acute myeloid leukemia (AML). This acquisition also marks Hanmi's strategic entry into North America, establishing a foothold for future partnerships and clinical expansion in the region. Aptose will be delisted from stock exchanges and no longer subject to Canadian securities reporting requirements.

Management Comments

• "This transaction not only offers a premium value for our minority shareholders but also enables Aptose to continue the development of TUS combined with standard treatment venetoclax plus azacitidine (VEN+AZA) for acute myeloid leukemia (AML) in the TUSCANY Phase 1/2 clinical study." William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer of Aptose.
• "We are extremely grateful for Hanmi’s ongoing support as we work toward our long-term goal of improving patient outcomes in AML." William G. Rice, Ph.D.
• "With a growing body of positive data, it is important to support the uninterrupted and expanded development of tuspetinib in the TUSCANY clinical study." Jae-Hyun Park of Hanmi.
• "This step also marks Hanmi’s first beachhead and direct entry into North America, establishing a strategic foothold for future partnerships and clinical expansion in the region." Jae-Hyun Park of Hanmi.

Industry Context

This acquisition reflects a broader trend in the biopharmaceutical industry where larger, established companies acquire smaller clinical-stage firms to gain access to promising drug candidates and expand their market presence. For Hanmi Pharmaceutical, a leading South Korean biopharmaceutical company, this transaction represents a strategic direct entry into the North American market, providing a "beachhead" for future expansion and partnerships. It also underscores the value placed on innovative oncology assets like tuspetinib, particularly in areas with high unmet medical needs such as acute myeloid leukemia.

Comparison to Industry Standards

• The C$2.41 per share acquisition price represents a 28% premium over Aptose's 30-day VWAP of C$1.88, which is a reasonable premium for a go-private transaction in the biotechnology sector, often falling within the 20-40% range depending on market conditions and strategic value.
• The valuation range provided by Locust Walk (C$1.00 to C$5.23) indicates a wide spectrum of potential values for Aptose, reflecting the inherent risks and potential upside of a clinical-stage biotechnology company. The C$2.41 offer falls within the lower-middle part of this range, suggesting a balance between immediate shareholder value and the risks associated with continued drug development.
• The continued development of tuspetinib (TUS) in combination with venetoclax plus azacitidine (VEN+AZA) for AML aligns with industry efforts to develop more effective triplet therapies for difficult-to-treat cancers, building on the success of venetoclax-based regimens. The reported 100% CR/CRh rate in 80mg and 120mg cohorts for TUS triplet therapy, including patients with TP53, RAS, and FLT3 mutations, is a strong early signal compared to historical response rates for standard therapies in these challenging patient populations.

Corporate Governance

Related Party Transactions

• Hanmi Pharmaceutical, through its subsidiary, is acquiring Aptose. Hanmi already owns 19.93% of Aptose's outstanding Common Shares and has provided over US$30 million in debt facilities to Aptose, making this a related-party transaction subject to minority shareholder approval under Multilateral Instrument 61-101.

Stakeholder Impact

• Shareholders: Minority shareholders will receive C$2.41 cash per share, providing a premium and liquidity. They will no longer hold shares in a public company.
• Employees: The business may experience significant disruptions, including potential loss of employees, due to transaction-related uncertainty and integration with Hanmi. Risks related to employee retention are explicitly mentioned.
• Patients: The acquisition is intended to ensure the uninterrupted and expanded development of tuspetinib (TUS) for AML, potentially benefiting patients awaiting new treatment options.
• Creditors: Hanmi has provided debt facilities, and the acquisition will likely impact the company's capital structure and debt obligations.
• Suppliers/Partners: The change in ownership could lead to changes in existing supplier relationships or future partnership strategies.

Next Steps

• Aptose will undergo a "Continuance" from a corporation incorporated under the Canada Business Corporations Act to a corporation continued under the Business Corporations Act (Alberta).
• A special meeting of Aptose shareholders will be held no later than January 16, 2026, to approve the Transaction, requiring approval from at least two-thirds (66 2/3%) of votes cast and a majority of minority shareholders.
• Obtain court approval for the Arrangement.
• Upon completion, Aptose will no longer be subject to Canadian securities reporting requirements.
• Common Shares will be delisted from all stock exchanges, including the TSX.

Key Dates

Recommendation

For existing shareholders, the recommendation is to hold shares to receive the C$2.41 cash per share, which represents a 28% premium over the 30-day VWAP. The transaction has been unanimously recommended by the independent Special Committee and the Board, and is subject to customary approvals, indicating a high likelihood of completion. For investors not currently holding shares, an arbitrage opportunity may exist if the stock trades below the offer price prior to closing.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Acquisition, Merger, Go Private, Tuspetinib, AML, Acute Myeloid Leukemia, Biotechnology, Pharmaceutical, Clinical Study, TUSCANY, TSX, Arrangement Agreement, Shareholder Value